Elevated PAPP-A sets alarm bells ringing in patients with cardiac chest pain
Goran Loncar1, Stephan von Haehling
1Cardiology Department, Zvezdara University Medical Center, Belgrade, Serbia.
Insights
Elevated pregnancy-associated plasma protein A (PAPP-A) levels in cardiac chest pain patients signal a fivefold increased risk of adverse cardiovascular events within 90 days. This novel marker offers prognostic value beyond traditional risk factors.
Area of Science:
- Cardiovascular Research
- Biochemical Markers
- Prognostic Indicators
Background:
- Novel biochemical markers are crucial for refining risk assessment in patients prone to adverse cardiac events.
- Pregnancy-associated plasma protein A (PAPP-A) is emerging as a significant prognostic marker, independent of conventional risk factors.
- PAPP-A is increasingly recognized for its role in indicating plaque destabilization within cardiovascular research.
Discussion:
- Higher serum PAPP-A levels (>34.6 mIU/l) in cardiac chest pain patients are independently linked to a significantly increased short-term risk of cardiovascular events.
- These events include myocardial infarction, ischemic stroke, stent thrombosis, and cardiovascular-related death within 90 days.
- Patients with PAPP-A levels above the threshold face a fivefold higher frequency of adverse cardiovascular events compared to those with lower levels.
Key Insights:
- Serum PAPP-A >34.6 mIU/l serves as a critical warning for heightened short-term cardiovascular event risk in chest pain patients.
- The prognostic information provided by PAPP-A is independent of traditional cardiovascular risk factors.
- A hazard ratio of 5.28 (95% CI: 3.81-7.31) underscores the substantial risk associated with elevated PAPP-A levels.
Outlook:
- Current evidence does not support PAPP-A as a diagnostic tool for acute coronary syndrome, especially when compared to troponin.
- PAPP-A's interaction with heparin may limit its practical clinical application.
- Further large-scale, multicenter studies are essential to validate PAPP-A's utility in routine clinical practice for cardiovascular risk stratification.
Abstract:
Novel biochemical markers may improve the estimation of overall risk in subjects at a high risk of adverse cardiac events. Measurement of some of these markers, including pregnancy-associated plasma protein A (PAPP-A), brings significant prognostic information independent of traditional risk factors. PAPP-A has been recently identified as a marker of plaque destabilization with growing interest in cardiovascular research. Our group has recently demonstrated that higher levels of serum PAPP-A were independently associated with an increased short-term risk of cardiovascular events in a large sample of 2568 consecutive patients presenting with cardiac chest pain. PAPP-A levels above 34.6 mIU/l in cardiac chest-pain patients sets alarm bells ringing as a warning for higher risk of short-term cardiovascular adverse events, including stent thrombosis, myocardial infarction, ischemic stroke or cardiovascular-related death within 90 days, the combined primary end point of this study. Cardiac chest pain patients with PAPP-A levels above 34.6 mIU/l may suffer from adverse cardiovascular events five times more frequently within 90 days than those with lower PAPP-A levels (hazard ratio: 5.28; 95% CI: 3.81-7.31). However, current data do not support the diagnostic role of PAPP-A for acute coronary syndrome in comparison to the gold standard biomarker troponin. Additionally, PAPP-A is known to interact with heparin, which may diminish its potential utility in every day clinical life. Future multicenter and large-volume studies are warranted to validate the use of PAPP-A in routine clinical practice.
More Related Videos
Related Concept Videos
Angina III: Clinical Manifestations and Assessment
Pericarditis II: Clinical Features and Diagnostic Tests
Acute Coronary Syndrome III: Diagnostic Studies
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Assessment of apical pulse
Assessing the apical pulse is a critical nursing procedure, particularly indicated for:
Introduction Cardiac Emergencies


